Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal peritoneal metastases - The Hong Kong experience and literature review
| Autor: | Dominic Chi-Chung Foo, R Wei, Ka Kin Ng, Jeremy Yip, Hok Kwok Choi, Oswens Siu-Hung Lo, Felix Che-Lok Chow |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male medicine.medical_specialty Time Factors Colorectal cancer Asian-pacific lcsh:Surgery Antineoplastic Agents Asymptomatic 03 medical and health sciences 0302 clinical medicine Symptom relief Drug Therapy medicine Humans Infusions Parenteral Peritoneal Neoplasms Aged Symptomatic relief Colorectal peritoneal neoplasms business.industry Appendiceal peritoneal metastases Retrospective cohort study lcsh:RD1-811 Cytoreduction Surgical Procedures Hyperthermia Induced Middle Aged medicine.disease Surgery Survival Rate Treatment Outcome Appendiceal Neoplasms 030220 oncology & carcinogenesis Peritoneal Cancer Index Hong Kong 030211 gastroenterology & hepatology Hyperthermic intraperitoneal chemotherapy Female medicine.symptom Cytoreductive surgery business Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) Colorectal Neoplasms |
| Zdroj: | Asian Journal of Surgery, Vol 44, Iss 1, Pp 221-228 (2021) |
| ISSN: | 0219-3108 |
| Popis: | Introduction: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is increasingly used to treat peritoneal metastases from appendiceal or colorectal origin. We evaluate our institution's experience and survival outcomes with this procedure, and its efficacy in symptom relief. Methods: This is a single-centre retrospective observational study on patients with peritoneal metastases (PM) from appendiceal neoplasm or colorectal cancer who underwent CRS/HIPEC in Queen Mary Hospital. Our primary endpoints were overall survival (OS) and morbidity and mortality of this procedure; secondary endpoints included disease-free survival (DFS) and symptom-free survival. Results: Between 2006 and 2018, thirty CRS/HIPEC procedures were performed for 28 patients – 17 (60.7%) had appendiceal PM while 11 (39.9%) had colorectal PM. The median peritoneal cancer index was 20; complete cytoreduction was achieved in 83.3% patients. High-grade morbidity occurred in 13.3% cases. There was no 30-day mortality. Two-year OS were 71.6% and 50% for low-grade appendiceal PM and colorectal PM patients (p = 0.20). Complete cytoreduction improved OS (2-year OS 75.4% vs 20%, p = 0.04). Median DFS was 11.8 months. Median symptom-free duration was 36.8 months; patients with complete cytoreduction were more likely to remain asymptomatic (82.9% at 1 year, vs 60% in incomplete cytoreduction group, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|